Physician profile
James Leroy Deterding
NPI 1396785994
$2,305.61
in general payments reported to CMS, 2019-2025
24 companies · $23.18 in 2025
The $23.18 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $533 · 2021: $719 · 2022: $43.06 · 2023: $208 · 2025: $23.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $185 · Food and Beverage: $46.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $185.00 |
| Food and Beverage | $46.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $374.17 | 2020-2021 | |
| Vifor Pharma, INC. | $350.26 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $275.66 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $195.65 | 2019 | |
| Glaxosmithkline, LLC. | $185.00 | 2023 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $163.77 | 2019-2021 | |
| Amgen INC. | $152.84 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $109.86 | 2021-2022 | |
| Horizon Therapeutics Plc | $88.05 | 2019-2021 | |
| Akebia Therapeutics INC | $69.70 | 2019-2021 | |
| Genzyme Corporation | $55.54 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.53 | 2021 | |
| Opko Pharmaceuticals, LLC | $45.41 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $38.93 | 2021-2025 | Crysvita |
| Shire North American Group INC | $20.49 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17.36 | 2020 | |
| Daiichi Sankyo INC. | $17.33 | 2021 | |
| Amicus Therapeutics, INC. | $16.71 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.35 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.57 | 2019 | |
| La Jolla Pharmaceutical Company | $13.38 | 2019 | |
| Fresenius USA Marketing, INC. | $12.75 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Deterding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.